Beta Drugs Limited H1 FY27 Revenue Rises 29% to ₹263 Crore

Beta Drugs Limited reported H1 FY27 consolidated revenue from operations of ₹263.04 crore, up 29.2% year-on-year from ₹203.6 crore, while profit after tax excluding minority interest rose to ₹34.3 crore. The result matters because the company maintained EBITDA margin near 23% while reporting growth across oncology, contract manufacturing, API and exports.

How did Beta Drugs perform in H1 FY27?

Beta Drugs reported consolidated revenue of ₹263.04 crore for the half-year ended September 2026, compared with ₹203.6 crore in H1 FY26. EBITDA increased to ₹61 crore from ₹47 crore, representing growth of about 30%, while the EBITDA margin was 23.18%, marginally above 23.08% a year earlier.

Profit after tax excluding minority interest rose to ₹34.3 crore from ₹23.9 crore. This represents growth of about 43.5%, although management commentary described PAT growth as 45%. PAT margin improved to 13.1% from 11.7%, supported by a higher gross margin and growth across the company’s operating businesses.

What drove Beta Drugs' revenue and margin improvement?

Growth was led by branded oncology, contract manufacturing and API operations. Branded oncology revenue rose 17% to about ₹71 crore in H1 FY27 from ₹60 crore in the previous-year period. The company said its top 10 brands contributed around half of its total topline.

Nivian Lifesciences, a focus brand, generated ₹31 crore in revenue and recorded 75% year-on-year growth. Contract manufacturing, or CMO, contributed ₹95 crore and grew 21%, which the company attributed to new customer additions and deeper supply relationships. The API business expanded by about 30% during the half-year.

Gross margin improved to 56.21% from 51.35%. Management attributed this expansion to higher realisations across key business lines. The reported margin outcome is notable because EBITDA margin remained broadly steady despite the company continuing investments in capacity and product development.

What did Beta Drugs report for the September quarter?

Beta Drugs reported consolidated revenue from operations of ₹137.49 crore for the quarter ended September 30, 2026, up 33% year-on-year from ₹103.39 crore and 9.51% sequentially from ₹125.55 crore. Total income for the quarter was ₹139.24 crore.

Quarterly profit before tax rose 56.8% year-on-year to ₹25.78 crore and increased 16.95% sequentially from ₹22.04 crore. Profit after tax after non-controlling interests reached ₹19.28 crore, up 16.98% from ₹16.49 crore in the June quarter.

The supplied quarterly filing data separately lists revenue of ₹58.0 crore, up 6.5% year-on-year, and net profit of ₹3.7 crore, up 145.7% year-on-year. The provided material does not specify how these figures relate to the consolidated September-quarter disclosures, so they should not be directly compared without reviewing the underlying filing basis.

How are exports and capacity plans shaping operations?

Export formulations contributed ₹43 crore in H1 FY27. Management said export growth normalised after excluding a prior-year one-off opportunity sale, with growth of 169% on that basis. The export business rebounded in the September quarter, recording 95% growth, according to the company’s commentary.

During H1 FY27, Beta Drugs filed 76 product dossiers and received 35 approvals in markets including Colombia, Peru, Jordan, Ethiopia and Tanzania. Its registration base stood at 415, with 872 registrations in the pipeline. Management expects export revenue to grow 30% for the full year, supported by existing orders and possible tender wins.

The company also said new API capacity is expected to become operational in Q4 FY27. At the Adley Formulations plant, production shutdowns linked to debottlenecking and capacity expansion affected branded oncology sales. Supply constraints in platinum APIs also delayed some orders, which management expects to fulfil in the second half.

What is Beta Drugs' FY27 outlook and regulatory position?

Beta Drugs reiterated its target to close FY27 with revenue of ₹535 crore or more and an EBITDA margin of 23% to 24%. Since H1 revenue was ₹263.04 crore, the target implies a stronger second-half contribution than the first half, subject to execution across its businesses.

Management guided for 20% to 25% growth across branded products, CMO, API, Nivian and exports. It also stated a medium-term growth expectation of 20% to 25% over the next three to five years. For FY27, the company is targeting 20% to 22% growth in branded oncology and more than 50% growth in Nivian.

The company said recent National Pharmaceutical Pricing Authority trade-margin capping guidelines had zero to negligible impact on its operations. This disclosure is relevant for investors because pharmaceutical pricing and trade-margin regulation can affect product economics, but Beta Drugs did not indicate a material effect from the guidelines in its results communication.

Why does the H1 FY27 result matter for investors?

The H1 numbers show that Beta Drugs expanded revenue and profit while holding EBITDA margin near its stated 23% to 24% range. Higher gross margin, growth in Nivian and CMO, and a recovery in exports were the main reported operating factors behind this performance.

The figures also place the company’s H1 PAT of ₹34.3 crore close to its reported full-year FY26 PAT of ₹41.4 crore. However, the FY27 revenue target depends on a larger second-half contribution, including fulfilment of delayed oncology orders, export execution and the planned commissioning of new API capacity.

Conclusion

Beta Drugs delivered 29.2% H1 FY27 revenue growth to ₹263.04 crore and lifted PAT to ₹34.3 crore, with EBITDA margin holding at 23.18%. The result was supported by growth in branded oncology, Nivian, CMO, APIs and export formulations, alongside a substantial increase in gross margin.

Investors will watch the company’s ability to meet its ₹535 crore-plus FY27 revenue target, maintain EBITDA margin within the 23% to 24% range, commission new API capacity in Q4 FY27 and convert its export registrations and pipeline into revenue.